[1] Swerdlow SH, Campo E, Harris NL, et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed[M] Lyon, France: IARC Press,2017.
[2] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[3] Jaffe E S, Arber DA, Campo E, et al.Hematopathology[M]. 2nd. Elsevier Health Sciences,2017,761-773.
[4] Mühlbacher V, Zenger M, Schnittger S, et al.Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%[J]. Genes Chromosomes Cancer,2014,53(6):524-536.
[5] Wang S, He G.2016 Revision to the WHO classification of acute lymphoblastic leukemia[J]. J Transl Int Med,2016,4(4):147-149.
[6] Bain B J.Leukaemia diagnosis[M]. 5th.John Wiley & Sons,2017:249-497.
[7] Swerdlow SH, Campo E, Pileri SA, et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood,2016,127(20):2375-2390.
[8] Hsi ED.2016 WHO Classification update-What's new in lymphoid neoplasms[J]. Int J Lab Hematol,2017,39(Suppl 1):14-22.
[9] Quintanilla-Martinez L.The 2016 updated WHO classification of lymphoid neoplasias[J]. Hematol Oncol,2017,35(Suppl 1):37-45.
[10] Jiang M, Bennani NN, Feldman AL.Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms[J]. Expert Rev Hematol,2017,10(3):239-249.
[11] Haroun F, Millado K, Tabbara I.Erdheim-Chester Di-sease: Comprehensive Review of Molecular Profiling and Therapeutic Advances[J]. Anticancer Res,2017,37(6):2777-2783. |
